IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is an American multinational corporation established in 1983 and headquartered in Westbrook, Maine, with a European headquarters in Hoofddorp, Netherlands. The company is a global leader in the development, manufacture, and distribution of innovative products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Its mission is to enhance the health and well-being of pets, people, and livestock, creating long-term value for its stakeholders.

IDEXX's comprehensive portfolio spans three main segments: Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD). Key offerings include in-clinic diagnostic instruments such as the Catalyst Dx Chemistry Analyzer, ProCyte Dx Hematology Analyzer, and SNAP tests, alongside advanced reference laboratory services. The company also provides practice management software like IDEXX Neo, diagnostic imaging solutions, and water testing products such as Colilert and Colisure. Additionally, IDEXX offers products for human point-of-care medical diagnostics through its OPTI Medical Systems.

Under the leadership of President and CEO Jay Mazelsky, IDEXX maintains a dominant position in the veterinary diagnostics market, holding approximately 45% market share in 2024. The company's market positioning is strengthened by its integrated diagnostic ecosystem, high customer retention rates, and continuous innovation. Recent notable developments include the UK availability of its Cancer Dx Panel for early detection of Canine Lymphoma in April 2026, the launch of the ImageVue DR50 Plus in January 2026, and the introduction of the revolutionary slide-free cellular analyzer, IDEXX inVue Dx™, in January 2024. IDEXX reported strong financial performance, including an earnings beat in Q4 2025 with $3.08 EPS and $4.30 billion in revenue.